

ACURA PHARMACEUTICALS, INC  
Form 8-K  
May 02, 2013

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934**

**May 2, 2013**

Date of Report (Date of earliest event reported)

**ACURA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

**State of New York**            **1-10113**                            **11-0853640**  
(State of Other Jurisdiction (Commission File Number) (I.R.S. Employer

of Incorporation)

Identification Number)

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

**Item 2.02 Results of Operations and Financial Condition**

On May 2, 2013 we issued a press release disclosing the financial results for our first quarter ended March 31, 2013. A copy of our press release is attached as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits**

**Exhibit Number Description**

99.1	Press Release dated May 2, 2013 Announcing Financial Results for the First Quarter of 2013
------	--

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: May 2, 2013

**Exhibit Index**

**Exhibit Number** **Description**

99.1	Press Release dated May 2, 2013 Announcing Financial Results for the First Quarter of 2013
------	--